{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:basiliximab sarotalocan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:felmetatug vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
Vaccine. Mar 2006;24(10):1726-33.: Phase 2 Human clinical trial Completed N/A
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:anselamimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:ecleralimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:cinaxadamtase alfa [INN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
INN:efimosfermin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
37-9.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class:
PROTEIN
